Canterbury DHB

Context

Burkitt Leukaemia/Lymphoma

This is a rare subtype of ALL (<5%). With intensive chemotherapy (e.g., LY10) survival in Burkitt Leukaemia and Lymphoma, i.e., patients with extensive disease, is more than 50%. In Burkitt Lymphoma allografting could be considered if CR is not achieved after the first 2 cycles of chemotherapy (Codox M and IVAC). Autografting could be considered in that situation if allografting is not practicable, and the disease can be controlled by another type of chemotherapy.

References

About this Canterbury DHB document (8151):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

December 2016

Next Review:

December 2018

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 8151